The discovery of INHBE and ALK7 as potential drug targets has opened up new avenues in the development of therapies for obesity and metabolic disorders.

By conducting in - depth searches in relevant databases, the development of drugs targeting MSTN/GDF8 and bone morphogenetic proteins (BMPs) has been revealed.

Through comprehensive searches in the Patsnap Synapse database, it has been found that the key drugs targeting ActRII mainly consist of fusion proteins and monoclonal antibodies.

In the pursuit of treating muscle - related diseases and achieving effective weight management with the goal of “fat loss with muscle gain”.

The Activin - ActRII - ActRI pathway plays a vital role in cell growth and differentiation, and understanding its mechanism of action is essential.

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry.

The Activin - ActRII - ActRI pathway is a key regulatory pathway in muscle growth and has attracted significant attention in the research of muscle - related diseases and weight - loss therapies.

With the widespread use of Semaglutide in weight management, the issue of weight rebound after discontinuation has emerged as a significant challenge.

Semaglutide has been increasingly utilized for chronic weight management in obese or overweight adults due to its remarkable weight - loss effects.

Suzetrigine received approval from the FDA on January 30, 2025, as a small-molecule pharmaceutical for the treatment of moderate to severe acute pain in adults.

The combination drug Meloxicam and Rizatriptan, received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025, for the treatment of migraine.

Limertinib is a newly developed small-molecule chemical drug, specifically designed as an inhibitor targeting the epidermal growth factor receptor (EGFR) T790M mutation.